Central diabetes insipidus induced by acute myeloid leukemia with DNMT3A mutation Journal Article


Authors: Lakshmanan, P.; Asnani, H.; Knorr, D.
Article Title: Central diabetes insipidus induced by acute myeloid leukemia with DNMT3A mutation
Abstract: Central diabetes insipidus (CDI) is an uncommon complication of acute myeloid leukemia (AML). Patients present with polyuria either preceding or at the time of diagnosis of AML. We describe the case of a 36-year-old male who presented with a subacute onset of polyuria, polydipsia, nocturia, and fatigue. After an extensive workup, he was diagnosed with AML/CMML (chronic myelomonocytic leukemia) with a normal karyotype with DNMT3A, CBFB, and PTPN11 mutations. Further workup of the polyuria with a water deprivation test helped confirm the diagnosis of CDI along with MRI findings suggestive of hypophysitis. In this report, we analyze the clinical workup for AML and CDI and report the possibility of extramedullary leukemic infiltration associated with DNMT3A mutation, which has been reported as one of the mechanisms in the existing literature. We also discuss other theories hypothesized to cause CDI in AML patients with abnormal karyotypes. Our patient progressed to AML from CMML-2 after a cycle of decitabine, with confirmed gingival and presumed central nervous system (CNS) involvement. He is in minimal residual disease (MRD)-negative complete remission after induction with a CNS-active acute lymphoblastic leukemia-2 regimen. He also received double umbilical cord blood transplantation, conditioned with cyclophosphamide, fludarabine, thiotepa, and total body irradiation (TBI) of 4 Gy. This was complicated by engraftment syndrome for which he is currently being managed. CDI of the patient was corrected by desmopressin administration. © 2022 Priyanka Lakshmanan et al.
Keywords: adult; clinical article; human tissue; chronic myelomonocytic leukemia; gene mutation; fludarabine; hydroxyurea; fatigue; case report; nuclear magnetic resonance imaging; follow up; disease association; anemia; fluid therapy; maintenance therapy; cyclophosphamide; thiotepa; cord blood stem cell transplantation; whole body radiation; bone marrow biopsy; minimal residual disease; contrast enhancement; prophylaxis; hospital admission; hospital discharge; blood cell count; diagnostic test; leukocytosis; disease exacerbation; serum osmolality; sodium urine level; urine osmolality; protein tyrosine phosphatase shp 2; induction chemotherapy; hypernatremia; vasopressin; leukemia remission; urine volume; central nervous system disease; dna methyltransferase 3a; allopurinol; hypophysitis; engraftment syndrome; hypophysis; acute myeloid leukemia; desmopressin; diabetes insipidus; polydipsia; polyuria; nocturia; decitabine; leukemic infiltration; gingiva disease; human; male; article; core binding factor beta; pituitary stalk; body temperature disorder; cold intolerance; t1 weighted imaging; water deprivation test
Journal Title: Case Reports in Endocrinology
Volume: 2022
ISSN: 2090-6501
Publisher: Hindawi Publishing Corporation  
Date Published: 2022-01-01
Start Page: 2750146
Language: English
DOI: 10.1155/2022/2750146
PROVIDER: scopus
PMCID: PMC9152344
PUBMED: 35656122
DOI/URL:
Notes: Article -- Export Date: 1 July 2022 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. David A Knorr
    21 Knorr